ClearPoint Neuro (NASDAQ:CLPT) Trading Up 7.4% - Should You Buy?

Key Points

• ClearPoint Neuro's stock price increased by 7.4% to $28.34, with about 318,362 shares traded, indicating a decrease in trading volume compared to its average.
• Analyst ratings for ClearPoint Neuro are mixed, with a consensus of "Moderate Buy" and a target price of $19.67, while one analyst has a "sell" rating.
• The company reported earnings of ($0.21) per share for the last quarter, underperforming the expected ($0.20), and has a significant negative net margin of 66.15%.

ClearPoint Neuro, Inc. (NASDAQ:CLPT - Get Free Report)'s share price was up 7.4% during trading on Wednesday . The company traded as high as $28.00 and last traded at $28.34. Approximately 318,362 shares traded hands during trading, a decline of 29% from the average daily volume of 445,331 shares. The stock had previously closed at $26.39.

Analyst Upgrades and Downgrades

Several equities analysts have commented on CLPT shares. Stifel Nicolaus raised their price target on shares of ClearPoint Neuro from $8.00 to $9.00 and gave the company a "buy" rating in a research report on Friday, August 1st. Weiss Ratings reiterated a "sell (d-)" rating on shares of ClearPoint Neuro in a research note on Wednesday. Finally, Wall Street Zen raised shares of ClearPoint Neuro from a "sell" rating to a "hold" rating in a research report on Saturday, September 13th. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, ClearPoint Neuro presently has a consensus rating of "Moderate Buy" and an average target price of $19.67.

ClearPoint Neuro Price Performance

The company has a 50-day simple moving average of $13.25 and a 200-day simple moving average of $12.62. The company has a debt-to-equity ratio of 1.46, a current ratio of 7.30 and a quick ratio of 6.45. The stock has a market cap of $822.91 million, a PE ratio of -35.89 and a beta of 1.19.

ClearPoint Neuro (NASDAQ:CLPT - Get Free Report) last posted its earnings results on Tuesday, August 12th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.01). The business had revenue of $9.22 million for the quarter, compared to analysts' expectations of $9.20 million. ClearPoint Neuro had a negative net margin of 66.15% and a negative return on equity of 94.44%. ClearPoint Neuro has set its FY 2025 guidance at EPS. Sell-side analysts anticipate that ClearPoint Neuro, Inc. will post -0.66 EPS for the current fiscal year.

Hedge Funds Weigh In On ClearPoint Neuro

A number of institutional investors and hedge funds have recently bought and sold shares of CLPT. Millennium Management LLC boosted its stake in ClearPoint Neuro by 156.3% during the 1st quarter. Millennium Management LLC now owns 741,193 shares of the company's stock valued at $8,813,000 after acquiring an additional 452,043 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of ClearPoint Neuro by 107.3% in the 2nd quarter. Geode Capital Management LLC now owns 624,800 shares of the company's stock valued at $7,461,000 after buying an additional 323,429 shares during the period. Lane Generational LLC lifted its holdings in shares of ClearPoint Neuro by 6.8% in the 2nd quarter. Lane Generational LLC now owns 258,427 shares of the company's stock worth $3,086,000 after purchasing an additional 16,382 shares during the last quarter. Goldman Sachs Group Inc. lifted its stake in ClearPoint Neuro by 98.3% in the first quarter. Goldman Sachs Group Inc. now owns 257,871 shares of the company's stock valued at $3,066,000 after buying an additional 127,823 shares during the last quarter. Finally, Conway Capital Management Inc. lifted its position in ClearPoint Neuro by 31.1% in the 1st quarter. Conway Capital Management Inc. now owns 211,325 shares of the company's stock valued at $2,513,000 after purchasing an additional 50,100 shares during the last quarter. Hedge funds and other institutional investors own 30.08% of the company's stock.

About ClearPoint Neuro

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.